Immunotherapy has become a fourth treatment method for cancer in addition to surgical treatment, radiation treatment and chemotherapy. For immunotherapy, a large supply of antigen-specific killer T cells are required. A team around Kaneko SHINZO at CiRA showed that when they used an iPS cell stock not derived from T cells (a HLA homologous iPS cell stock) and introduced T-cell receptors with appropriate antigen information, they could prepare regenerative killer T cells with full antigen specificity. The T-iPS cells were successfully tested in mouse models

AMED news release, November 16, 2018